Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 12 of 33 · 1560 articles
People with IBD and their clinicians need to know whether common IBD treatments change COVID-19 risk or should be stopped. This review provides practical recommendations (continue most maintenance drugs; avoid systemic...
A blood biomarker that reliably indicates mucosal healing could reduce reliance on colonoscopy, help monitor disease activity more frequently, and better guide treatment decisions in UC.
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Gastro hep...
The work identifies factors that predict loss of response to infliximab and suggests maintenance drug levels are the strongest predictor, which could influence monitoring strategies for people with Crohn's disease on...
Serum LRG1 is a candidate blood biomarker for mucosal inflammation in UC, but anti-TNF drugs may suppress its levels and cause false-negative results. This affects noninvasive monitoring and decisions based on LRG1...
Severe UC flares can produce extreme but reversible hyperglycemia that may look like new-onset diabetes, so patients and clinicians should monitor and re-evaluate glucose over time rather than assuming a permanent...
If you have isolated perianal fistulizing Crohn’s disease, this large multicenter cohort shows about one-third later developed luminal Crohn’s disease over long-term follow-up, but many did not — underscoring variable...
This paper links preclinical models and a short Phase 2a trial to show a candidate SIK2/SIK3 inhibitor (GLPG3970) produced anti-inflammatory and mucus-restoring signatures in IBD tissues. If findings hold in larger...
Imaging found increased visceral fat in children with Crohn's despite normal BMI, which could reveal inflammation-related risk not apparent from weight alone. Visceral adiposity was linked to markers of inflammation and...
If validated, serum osmolality — a routine, low-cost blood measure — could become an additional marker to help identify IBD in certain hospitalized patients with anxiety. This could aid research and possibly improve...
Patients with ulcerative colitis may develop advanced neoplasia after seemingly complete endoscopic removal of dysplasia. Detecting genomic alterations in adjacent, histologically normal margins could identify...
Depression and GI diseases often co-occur; knowing which tends to appear first — and that this varies by subtype — can help clinicians prioritize screening and integrated care.
Monogenic causes (especially IL-10RA mutations) are common in infant-onset IBD and are linked to more severe disease and higher mortality; early genetic testing and consideration of HSCT may change prognosis.
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
This study suggests that cumulative infliximab exposure over time (AUC) — not just trough levels — may predict infection risk in people with IBD. That could affect how clinicians use therapeutic drug monitoring to...
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...
The paper provides genetic evidence that acute pancreatitis and Crohn’s disease share polygenic risk and converge on immune and inflammatory pathways; this may explain some observed comorbidity and points to biological...
Family history of CRC raises an individual’s absolute CRC risk whether or not they have IBD, and people with IBD who have multiple first‑degree relatives with CRC appear to have the largest increase in absolute risk....
The 5-year PROFILE follow-up is presented as strong evidence that early, effective therapy (in this case infliximab plus an immunomodulator) can change the long-term course of Crohn’s disease by lowering surgery rates...
The review directly compares randomized-trial evidence for JAK inhibitors in moderate-to-severe Crohn's disease and highlights which regimens (notably upadacitinib) showed the most consistent efficacy signals,...
People with suspected or known IBD and their clinicians want accurate, noninvasive tests to detect inflammation. This review suggests NGAL may be sensitive for identifying IBD but existing data are limited and uncertain,...
Non-invasive blood biomarkers that predict who will respond to therapy could help personalize treatment and avoid ineffective medications. This study identifies plasma miR-145 and miR-191 as potential predictors of...
Children with newly diagnosed ulcerative colitis in this study commonly had reduced muscle mass (sarcopenia) at diagnosis, and the degree of muscle loss correlated with higher disease activity and inflammation....
If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.
This trial is testing risankizumab in children with moderate-to-severe Crohn’s disease to learn how the drug behaves in kids, whether it’s safe, and whether it reduces disease activity — information that could expand...
This trial tests a safe, non-drug supplement (GlcNAc) as a precision-medicine approach for Crohn's disease based on a genetic variant that affects glycosylation. If successful, it could offer a new, well-tolerated...
Low muscle mass before ileocolic resection appears linked to higher short-term surgical complications and higher rates of endoscopic recurrence — information that could affect preoperative assessment and planning for...
Patient-centered measures help clinics track and improve care experiences important to people with IBD. A validated patient-developed PREM could better reflect patient priorities and support quality improvement in UK IBD...
Wearable-derived digital biomarkers aim to detect flares earlier and reduce reliance on questionnaires; patients' acceptance is essential for real-world use. High reported willingness suggests patient-centered...
Trials testing intestinal ultrasound–guided treat-to-target strategies and late-stage therapies could change how Crohn’s disease is monitored and treated if they show improved outcomes.
Cure8 could only read part of this source from Frontline Gastroenterology, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Infliximab.
Knowing a patient’s estimated infliximab clearance before starting rescue therapy for acute severe ulcerative colitis could help identify who may need higher or intensified induction dosing and who might be at greater...
The study suggests there may be stage-specific differences in mucosal IgA and IgG plasma cell patterns in UC, which could help researchers understand mucosal immunity changes across active disease, quiescence, and...
This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...
People with IBD who are treated with anti‑TNFα drugs commonly develop inflammatory or infectious skin problems. This study aims to clarify whether Staphylococcus aureus is more abundant in those lesions and whether its...
This trial studies adalimumab safety and pediatric dosing in children with moderate–severe Crohn's disease, which is directly relevant to families and clinicians considering anti-TNF therapy for pediatric IBD.
Intestinal ultrasound can assess IBD inflammation without radiation but interpretation varies by operator. Developing AI tools to measure bowel wall thickness and other features could standardize and speed image...
People with IBD (ulcerative colitis or Crohn’s/regional enteritis) may develop vitamin K–related hypoprothrombinemia; this updated label describes when and how vitamin K (phytonadione) is used and emphasizes INR...
Patients and clinicians want to know whether tofacitinib raises blood clotting or platelet activation risk in ulcerative colitis, because similar safety concerns were reported in other diseases.
ITB can closely mimic Crohn’s disease, so this study is relevant because it describes diagnostic test yields and illustrates that targeted TB testing and therapeutic trials of antituberculosis treatment can help...
Researchers and clinicians interested in cross-disease host–microbe interactions may find that an IBD–CRC shared microbial/host signature could have prognostic importance beyond the gut, here in bladder cancer.
The study explores using coordinated, longitudinal multi-omic profiles to better detect true responses to anti-TNF therapy and to inform personalized treatment selection for people with IBD.
Fatigue affects more than half of people with IBD and is a leading cause of impaired quality of life. A machine-learning approach that identifies distinct patient-level patterns may help researchers and clinicians...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from Gastroenterology & hepatology.
Real-world 52-week data suggest mirikizumab can produce meaningful remission and reasonable drug persistence in patients with treatment-experienced ulcerative colitis. This is especially relevant for people who have not...
Simple, routinely measured nutritional scores were associated with early (14-week) remission on vedolizumab in patients with moderate-to-severe UC, which could help identify patients more likely to respond early to this...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Biochemia medica.
The study suggests ADHD and autism are linked with slightly higher risk of more severe IBD events (including need for advanced therapies and, for UC, colectomy), which may help target monitoring and support for young...
